These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 31246158)

  • 1. Effect of delayed plasma centrifugation on equine adrenocorticotropic hormone concentration.
    Shepard KN; Haffner JC; Neal DL; Grubbs ST; Pearce GL
    J Vet Diagn Invest; 2019 Jul; 31(4):585-587. PubMed ID: 31246158
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of sample handling and N-phenylmaleimide on concentration of adrenocorticotrophic hormone in equine plasma.
    Rendle DI; Litchfield E; Gough S; Cowling A; Hughes KJ
    Equine Vet J; 2015 Sep; 47(5):587-91. PubMed ID: 24980684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigation of rhythms of secretion and repeatability of plasma adrenocorticotropic hormone concentrations in healthy horses and horses with pituitary pars intermedia dysfunction.
    Rendle DI; Litchfield E; Heller J; Hughes KJ
    Equine Vet J; 2014 Jan; 46(1):113-7. PubMed ID: 23742059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of freeze-thaw cycles on determination of immunoreactive plasma adrenocorticotrophic hormone concentrations in horses.
    Hu K; Stewart AJ; Yuen KY; Hinrichsen S; Dryburgh EL; Bertin FR
    J Vet Intern Med; 2020 May; 34(3):1350-1356. PubMed ID: 32255541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of adrenocorticotrophic hormone as a potential biomarker of pituitary pars intermedia dysfunction in horses.
    Lee ZY; Zylstra R; Haritou SJ
    Vet J; 2010 Jul; 185(1):58-61. PubMed ID: 20537574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circannual variation in plasma adrenocorticotropic hormone concentrations in the UK in normal horses and ponies, and those with pituitary pars intermedia dysfunction.
    Copas VE; Durham AE
    Equine Vet J; 2012 Jul; 44(4):440-3. PubMed ID: 21848531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of combined testing to simultaneously diagnose pituitary pars intermedia dysfunction and insulin dysregulation in horses.
    Horn R; Bertin FR
    J Vet Intern Med; 2019 Sep; 33(5):2249-2256. PubMed ID: 31498947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adrenocorticotropin concentration following administration of thyrotropin-releasing hormone in healthy horses and those with pituitary pars intermedia dysfunction and pituitary gland hyperplasia.
    Beech J; Boston R; Lindborg S; Russell GE
    J Am Vet Med Assoc; 2007 Aug; 231(3):417-26. PubMed ID: 17669045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Investigation of single and paired measurements of adrenocorticotropic hormone for the diagnosis of pituitary pars intermedia dysfunction in horses.
    Rendle DI; Duz M; Beech J; Parkin T; Durham AE
    J Vet Intern Med; 2015 Jan; 29(1):355-61. PubMed ID: 25312676
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BEVA primary care clinical guidelines: Diagnosis and management of equine pituitary pars intermedia dysfunction.
    Menzies-Gow NJ; Banse HE; Duff A; Hart N; Ireland JL; Knowles EJ; McFarlane D; Rendle D
    Equine Vet J; 2024 Mar; 56(2):220-242. PubMed ID: 37795557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of cortisol and ACTH responses after administration of thyrotropin releasing hormone in normal horses and those with pituitary pars intermedia dysfunction.
    Beech J; Boston R; Lindborg S
    J Vet Intern Med; 2011; 25(6):1431-8. PubMed ID: 22092639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of plasma ACTH, alpha-melanocyte-stimulating hormone, and insulin concentrations during various photoperiods in clinically normal horses and ponies and those with pituitary pars intermedia dysfunction.
    Beech J; Boston RC; McFarlane D; Lindborg S
    J Am Vet Med Assoc; 2009 Sep; 235(6):715-22. PubMed ID: 19751169
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of season and pasture grazing with blood hormone and metabolite concentrations in horses with presumed pituitary pars intermedia dysfunction.
    Frank N; Elliott SB; Chameroy KA; Tóth F; Chumbler NS; McClamroch R
    J Vet Intern Med; 2010; 24(5):1167-75. PubMed ID: 20666984
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Venipuncture does not affect adrenocorticotropic hormone concentration in horses.
    Fouché N; van der Kolk JH; Bruckmaier RM; Luz I; Foerster G; Gerber V
    Vet Rec; 2015 Sep; 177(9):223. PubMed ID: 26246396
    [No Abstract]   [Full Text] [Related]  

  • 15. Comparison of two methods for measurement of equine adrenocorticotropin.
    Banse HE; Schultz N; McCue M; Geor R; McFarlane D
    J Vet Diagn Invest; 2018 Mar; 30(2):233-237. PubMed ID: 29284383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. α-Melanocyte--stimulating hormone and adrenocorticotropin concentrations in response to thyrotropin-releasing hormone and comparison with adrenocorticotropin concentration after domperidone administration in healthy horses and horses with pituitary pars intermedia dysfunction.
    Beech J; McFarlane D; Lindborg S; Sojka JE; Boston RC
    J Am Vet Med Assoc; 2011 May; 238(10):1305-15. PubMed ID: 21568777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation of pituitary histomorphometry with adrenocorticotrophic hormone response to domperidone administration in the diagnosis of equine pituitary pars intermedia dysfunction.
    Miller MA; Pardo ID; Jackson LP; Moore GE; Sojka JE
    Vet Pathol; 2008 Jan; 45(1):26-38. PubMed ID: 18192571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of pituitary pars intermedia dysfunction and Prascend (pergolide tablets) treatment on endocrine and immune function in horses.
    Miller AB; Loynachan AT; Bush HM; Hart KA; Barker VD; Campana-Emard AG; Grubbs ST; Adams AA
    Domest Anim Endocrinol; 2021 Jan; 74():106531. PubMed ID: 32942194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic and pharmacodynamic properties of pergolide mesylate following long-term administration to horses with pituitary pars intermedia dysfunction.
    McFarlane D; Banse H; Knych HK; Maxwell LK
    J Vet Pharmacol Ther; 2017 Apr; 40(2):158-164. PubMed ID: 27301465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of basal plasma α-melanocyte-stimulating hormone and adrenocorticotrophic hormone concentrations for the diagnosis of pituitary pars intermedia dysfunction from a population of aged horses.
    Mc Gowan TW; Pinchbeck GP; Mc Gowan CM
    Equine Vet J; 2013 Jan; 45(1):66-73. PubMed ID: 22563728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.